hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Withdrawals === 1 January 2009 – The U.S.–Iraq Status of Forces Agreement went into effect, and gave the Government of Iraq de jure responsibility of maintaining and providing security for all of its people. Approximately 150,000 foreign troops in Iraq. 28 June 2009 – Foreign forces were no longer stationed within any of Iraq's major cities. Proclaimed as a national holiday by Iraqi Prime Minister Nouri al-Maliki. 31 July 2009 – The last large groups of non-U.S. foreign forces completed their withdrawal from Iraq. 1 January 2010 – The major commands Multi-National Force – Iraq, Multi-National Corps – Iraq and Multi-National Security Transition Command – Iraq merged into the unified command United States Forces – Iraq, reducing the total number of staff positions by 41%. Approximately 112,000 U.S. troops in Iraq. 7 March 2010 – Iraq held parliamentary elections, its second under its democratic constitution, and is seen as an important milestone for the young Iraqi political system; this leaves approximately 96,000 U.S. troops in Iraq. 1 September 2010 – American forces ceased all combat operations, i.e. patrolling, serving arrest warrants, route clearance, etc., and transitioned to a pure advise, train and assist role. Operation Iraqi Freedom is officially concluded, and the advise and assist mission continues under Operation New Dawn. 49,700 U.S. troops in Iraq. 31 December 2011 – U.S. Army and U.S. Marine Corps units and formations complete their withdrawal from Iraq.
== Domains and major indicators == Indicators of positive health generally include Life style (sociology) parameters such as social interaction, diet, physical activity, water intake, sleep and relaxation, and yoga and meditation. But most of these defy direct measurement. Such lifestyle factors modulate medical parameters such as Immunity (medicine) level and hormonal balance, and these parameters are objectively measurable. On the pattern of quality-of-life measurement, these parameters are divided into 5 domains, each comprising several parameters. The following domains and major parameters have been suggested to measure positive health.
For the 2005 sequel The Ring Two, Chase was credited due to the use of archival footage from the first film, although actress Kelly Stables performed all the new on-screen material and motion capture for Samara. Between 2003 and 2004, Chase held a main cast role as Joyce, the quirky girlfriend of the title character, in the Fox period sitcom Oliver Beene. Her other notable credits during this period included the direct-to-video film Beethoven's 5th (2003) and the romantic comedy Carolina (2003), in which she played the younger version of Julia Stiles' character.
Sources: en.wikipedia.org
Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman who is the CEO of the Novo Nordisk Foundation and former executive vice president of research & development (R&D), head of R&D and chief scientific officer at the pharmaceutical company Novo Nordisk.
== Effects on chronic pain == Data obtained from using P2 receptor-selective antagonists has produced evidence supporting ATP's ability to initiate and maintain chronic pain states after exposure to noxious stimuli. It is believed that ATP functions as a pronociceptive neurotransmitter, acting at specific P2X and P2Y receptors in a systemized manner, which ultimately (as a response to noxious stimuli) serve to initiate and sustain heightened states of neuronal excitability. This recent knowledge of purinergic receptors' effects on chronic pain provide promise in discovering a drug that specifically targets individual P2 receptor subtypes. While some P2 receptor-selective compounds have proven useful in preclinical trials, more research is required to understand the potential viability of P2 receptor antagonists for pain. Recent research has identified a role for microglial P2X receptors in neuropathic pain and inflammatory pain, especially the P2X4 and P2X7 receptors.
A fatality was narrowly avoided when Leonov's spacesuit expanded in the vacuum of space, preventing him from re-entering the airlock. To overcome this, he had to partially depressurize his spacesuit to a potentially dangerous level. He succeeded in safely re-entering the spacecraft, but he and Belyayev faced further challenges when the spacecraft's atmospheric controls flooded the cabin with 45% pure oxygen, which had to be lowered to acceptable levels before re-entry. The reentry involved two more challenges: an improperly timed retrorocket firing caused the Voskhod 2 to land 386 kilometers (240 mi) off its designated target area, the city of Perm; and the instrument compartment's failure to detach from the descent apparatus caused the spacecraft to become unstable during reentry. By October 16, 1964, Leonid Brezhnev and a small cadre of high-ranking Communist Party officials deposed Khrushchev as Soviet government leader a day after Voskhod 1 landed, in what was called the "Wednesday conspiracy". The new political leaders, along with Korolev, ended the technologically troublesome Voskhod program, canceling Voskhod 3 and 4, which were in the planning stages, and started concentrating on reaching the Moon. Voskhod 2 ended up being Korolev's final achievement before his death on January 14, 1966, as it became the last of the space firsts that the USSR achieved during the early 1960s.
=== Services === As of 2025–26, the services sector was the largest contributor to Pakistan's GDP, accounting for 58.42% of GDP. The sector accounted for 41.6% of total employment in 2024–25. In the International Telecommunication Union's ICT Development Index, Pakistan's score increased from 56.4 in 2025 to 67.7 in 2026, an increase of 20% from 2025. Approximately 57% of Pakistan's population used the Internet in 2024. In fiscal year 2023–24, Pakistan's ICT exports rose to a record $2.6 billion. Pakistan ranks among the world's top five freelancing markets, with an estimated three million freelancers. During the first ten months of fiscal year 2025–26, freelancers earned more than US$950 million in foreign exchange.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.